Synapse - Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)

Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL) Meeting Abstract

Authors:	Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; Lue, J. K.; Goldberg, A. D.; Stephens, D. M.; Duffy, V.; Panton, G.; Tyznar, D.; Dorsey, C.; Soni, D.; Hutzler, C.; Nogan, L.; Allen, A.; Nyima, T.; Nguyen, T. Q.; Shah, M.; Cook, T. R.; Abillar-Wright, J.; Brutus, J.; Laudati, C.; Kikani, B.; Coombs, C. C.; Silvestrone, M. R.; Jensen, C. E.; Fakhri, B.; Thompson, M. C.
Abstract Title:	Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
Meeting Title:	66th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	144
Issue:	Suppl. 1
Meeting Dates:	2024 Dec 7-10
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2024-11-05
Start Page:	1011
Language:	English
ACCESSION:	WOS:001412773700004
DOI:	10.1182/blood-2024-203807
PROVIDER:	wos
Notes:	Source: Wos